Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma
…, K Ideguchi, T Yasumitsu, K Nakagawa… - The Annals of thoracic …, 2004 - Elsevier
BACKGROUND: A pulmonary metastasectomy for colorectal carcinoma is a generally accepted
procedure, although several prognostic predictors have been reported. The aim of this …
procedure, although several prognostic predictors have been reported. The aim of this …
Hypertonic saline versus mannitol for the treatment of elevated intracranial pressure: a meta-analysis of randomized clinical trials
Objectives: Randomized trials have suggested that hypertonic saline solutions may be superior
to mannitol for the treatment of elevated intracranial pressure, but their impact on clinical …
to mannitol for the treatment of elevated intracranial pressure, but their impact on clinical …
Viral and cellular mRNA translation in coronavirus-infected cells
K Nakagawa, KG Lokugamage, S Makino - Advances in virus research, 2016 - Elsevier
Coronaviruses have large positive-strand RNA genomes that are 5′ capped and 3′
polyadenylated. The 5′-terminal two-thirds of the genome contain two open reading frames (…
polyadenylated. The 5′-terminal two-thirds of the genome contain two open reading frames (…
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an …
…, E Shimizu, H Saito, S Toyooka, K Nakagawa… - The lancet …, 2010 - thelancet.com
Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal
growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase …
growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase …
[HTML][HTML] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
AT Shaw, DW Kim, K Nakagawa, T Seto… - … England Journal of …, 2013 - Mass Medical Soc
Background In single-group studies, chromosomal rearrangements of the anaplastic lymphoma
kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an …
kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an …
[HTML][HTML] First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Background The efficacy of the ALK inhibitor crizotinib as compared with standard
chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer (NSCLC) …
chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer (NSCLC) …
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer
…, G Giaccone, T Tamura, K Nakagawa… - Journal of clinical …, 2003 - ascopubs.org
Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839];
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …
Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial
…, H Shirato, M Tago, K Nakagawa, T Toyoda, K Hatano… - Jama, 2006 - jamanetwork.com
ContextIn patients with brain metastases, it is unclear whether adding up-front whole-brain
radiation therapy (WBRT) to stereotactic radiosurgery (SRS) has beneficial effects on …
radiation therapy (WBRT) to stereotactic radiosurgery (SRS) has beneficial effects on …
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the …
…, M Shah, R Shapira-Frommer, K Nakagawa… - The Lancet …, 2020 - thelancet.com
Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of high …
response to immune checkpoint blockade. We prospectively explored the association of high …
[HTML][HTML] Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
BT Li, EF Smit, Y Goto, K Nakagawa… - … England Journal of …, 2022 - Mass Medical Soc
Background Human epidermal growth factor receptor 2 (HER2)–targeted therapies have
not been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …
not been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …